These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18559575)

  • 1. Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.
    Steeg PS
    Clin Cancer Res; 2008 Jun; 14(12):3643-5. PubMed ID: 18559575
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding the Cause and Consequence of Tumor Heterogeneity.
    Khatib S; Pomyen Y; Dang H; Wang XW
    Trends Cancer; 2020 Apr; 6(4):267-271. PubMed ID: 32209440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs as Biomarker for Breast Cancer.
    Aggarwal T; Wadhwa R; Gupta R; Paudel KR; Collet T; Chellappan DK; Gupta G; Perumalsamy H; Mehta M; Satija S; Hansbro PM; Dua K; Maurya PK
    Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1597-1610. PubMed ID: 32342824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the biology of cancer stem cells in breast cancer.
    García Bueno JM; Ocaña A; Castro-García P; Gil Gas C; Sánchez-Sánchez F; Poblet E; Serrano R; Calero R; Ramírez-Castillejo C
    Clin Transl Oncol; 2008 Dec; 10(12):786-93. PubMed ID: 19068449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ErbB4 in breast cancer.
    Sundvall M; Iljin K; Kilpinen S; Sara H; Kallioniemi OP; Elenius K
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):259-68. PubMed ID: 18454307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers.
    Shi YJ; Tsang JY; Ni YB; Tse GM
    Oncologist; 2017 Apr; 22(4):487-490. PubMed ID: 28341760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heading in a new direction: drug permeability in breast cancer brain metastasis.
    Sledge GW
    Clin Cancer Res; 2010 Dec; 16(23):5605-7. PubMed ID: 21045085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
    Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative Bioinformatics Analysis Reveals Potential Target Genes and TNFα Signaling Inhibition by Brazilin in Metastatic Breast Cancer Cells.
    Hermawan A; Putri H
    Asian Pac J Cancer Prev; 2020 Sep; 21(9):2751-2762. PubMed ID: 32986377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
    Santa-Maria CA; Gradishar WJ
    JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
    Zhang CC; Pavlicek A; Zhang Q; Lira ME; Painter CL; Yan Z; Zheng X; Lee NV; Ozeck M; Qiu M; Zong Q; Lappin PB; Wong A; Rejto PA; Smeal T; Christensen JG
    Clin Cancer Res; 2012 Sep; 18(18):5008-19. PubMed ID: 22806875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
    DeMichele A; Yee D; Esserman L
    N Engl J Med; 2017 Dec; 377(23):2287-2289. PubMed ID: 29211674
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
    Horii R; Nitta H; Nojima M; Maruyama R; Ueno T; Ito Y; Ohno S; Banks P; Kanda H; Akiyama F
    Virchows Arch; 2021 Jul; 479(1):13-21. PubMed ID: 33496805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer.
    Burrell RA; Juul N; Johnston SR; Reis-Filho JS; Szallasi Z; Swanton C
    J Cell Biochem; 2010 Nov; 111(4):782-90. PubMed ID: 20665662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for the discovery and development of therapies for metastatic breast cancer.
    Eckhardt BL; Francis PA; Parker BS; Anderson RL
    Nat Rev Drug Discov; 2012 Jun; 11(6):479-97. PubMed ID: 22653217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
    Wang Y; Yan L; Zhang L; Xu H; Chen T; Li Y; Wang H; Chen S; Wang W; Chen C; Yang Q
    Int J Oncol; 2018 Sep; 53(3):1043-1054. PubMed ID: 30015868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1α,25-Dihydroxyvitamin D Inhibits the Metastatic Capability of MCF10CA1a and MDA-MB-231 Cells in an In Vitro Model of Breast to Bone Metastasis.
    Wilmanski T; Barnard A; Parikh MR; Kirshner J; Buhman K; Burgess J; Teegarden D
    Nutr Cancer; 2016 Oct; 68(7):1202-9. PubMed ID: 27552186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds.
    Ózsvári B; Sotgia F; Lisanti MP
    Aging (Albany NY); 2020 May; 12(11):10162-10179. PubMed ID: 32452826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relation between ACKR4 and CCR7 genes expression and breast cancer metastasis.
    Mohammed MM; Shaker O; Ramzy MM; Gaber SS; Kamel HS; Abed El Baky MF
    Life Sci; 2021 Aug; 279():119691. PubMed ID: 34102193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression.
    Sgarra R; Pegoraro S; Ros G; Penzo C; Chiefari E; Foti D; Brunetti A; Manfioletti G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):216-229. PubMed ID: 29518471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.